Federated Hermes
EWTX icon

Federated Hermes’s Edgewise Therapeutics EWTX Stock Holding History

Federated Hermes’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.79M Sell
56,778
-25,318
-31% -$730K ﹤0.01% 993
2025
Q4 		$2.04M Buy
82,096
+22,840
+39% +$458K ﹤0.01% 955
2025
Q3 		$961K Sell
59,256
-257,244
-81% -$3.65M ﹤0.01% 1161
2025
Q2 		$4.15M Buy
316,500
+316,420
+395,525% +$4.56M 0.01% 769
2025
Q1 		$1.76K Sell
80
-27
-25% -$708 ﹤0.01% 1959
2024
Q4 		$2.86K Sell
107
-2
-2% -$64 ﹤0.01% 1949
2024
Q3 		$2.91K Sell
109
-46,125
-100% -$918K ﹤0.01% 1913
2024
Q2 		$833K Buy
+46,234
New +$806K ﹤0.01% 1170
2023
Q4 		– Sell
-355
Closed -$2.03K – 2086
2023
Q3 		$2.03K Sell
355
-2
-0.6% -$14 ﹤0.01% 1968
2023
Q2 		$2.77K Sell
357
-8,746
-96% -$73.8K ﹤0.01% 1974
2023
Q1 		$60.7K Buy
9,103
+1,392
+18% +$12.9K ﹤0.01% 1718
2022
Q4 		$68.9K Buy
+7,711
New +$72.3K ﹤0.01% 1680
2022
Q1 		– Sell
-147,075
Closed -$2.25M – 2231
2021
Q4 		$2.25M Sell
147,075
-552,925
-79% -$9.95M ﹤0.01% 1016
2021
Q3 		$11.6M Hold
700,000
– – 0.02% 606
2021
Q2 		$14.9M Buy
700,000
+83,276
+14% +$2.28M 0.03% 551
2021
Q1 		$20M Buy
+616,724
New +$20M 0.04% 497

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Federated Hermes's EWTX Position: Q1 2026 in Review

Federated Hermes reduced its Edgewise Therapeutics (EWTX) stake by 31% in Q1 2026, selling an estimated $730K and leaving 56,778 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #993.

Federated Hermes first reported a position in EWTX in Q1 2021 and has held it in 16 quarters since. The position peaked at $20M in Q1 2021. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Federated Hermes held 56,778 shares of Edgewise Therapeutics worth $1.79M as of Q1 2026.
  • Federated Hermes sold 25,318 Edgewise Therapeutics shares in Q1 2026, an estimated $730K.
  • Edgewise Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #993 holding.
  • Federated Hermes first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • Federated Hermes's Edgewise Therapeutics position peaked at $20M in Q1 2021.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.